From Our Partners
Thursday, June 23, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

InBios, UN-Reno Partner to Develop Diagnostic for Melioidosis

by Global Biodefense Staff
August 9, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a grant to researchers at the University of Nevada, Reno and their collaborator, InBios International of Seattle, to further development of a rapid diagnostic for melioidosis.

Also known as Whitmore’s disease, melioidosis is a difficult to treat infection caused by Burkholderia pseudomallei, a Category B biothreat as classified by the Centers for Disease Control and Prevention.

Melioidosis is predominately a disease of tropical climates, especially in Southeast Asia and northern Australia where it is widespread. The B. pseudomallei bacteria causing melioidosis are found in contaminated water and soil. It is spread to humans and animals through direct contact with the contaminated source, is easily aerosolized and has a high mortality rate.

With NIAID’s two-year Phase I Small Business Technology Transfer (STTR) grant, the recipients will further development of their Active Melioidosis Detect (AMD) test.

“Results so far are very encouraging,” said David AuCoin, Principle Investigator at the Diagnostics Discovery Laboratory, University of Nevada School of Medicine. “We have a prototype of the product in Thailand and Australia now, regions that are hardest hit, to evaluate its effectiveness in endemic settings.”

Currently, there are no validated diagnostic products for melioidosis, and patient samples must be cultured, taking three to seven days to diagnose the disease. “Unfortunately, melioidosis can kill you well before the diagnosis is confirmed,” said AuCoin.

AuCoin produced and has been working with the monoclonal antibody used in the test since 2009. The work is also partially funded by the Pacific Southwest Regional Center for Excellence in Biodefense and Emerging Infections.

The team is working to secure Phase II funding following the two years of Phase I work, which will allow another three years of product development to generate the necessary preclinical studies to submit an application to the FDA for approval to distribute the assay.

Source: UN-Reno

From Our Partners
Tags: AwardsBurkholderia

Related Posts

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps
Outbreak News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC